OpenDNA bridges this gap by integrating AI-powered genetic and clinical data into everyday practice for smarter disease prediction and prevention. Their platforms make risk clear, actionable, and personal – empowering clinicians and patients to improve health outcomes. Read below how OpenDNA’s collaborations and AI technology are saving lives, improving the quality of life, and significantly reducing healthcare costs worldwide.
Company Overview
OpenDNA continues to lead in the integration of genomics, polygenic risk scoring, and artificial intelligence to predict and prevent chronic diseases—including cardiometabolic conditions, cancer, autoimmune, neurological, and ocular diseases. Our SaaS platform seamlessly connects with leading EMRs such as AthenaHealth, delivering AI-powered healthcare management plans that support clinicians in identifying and managing high-risk patients through advanced genetic and clinical data analysis.
Commercial Progress
- Product Expansion: In Q1, OpenDNA broadened its offerings from cardiovascular and cancer risk assessments to comprehensive full-body risk evaluations, now covering 32 distinct diseases. We also introduced a panel for monogenic cancer risk.
- Strategic Partnerships: In Q3, we signed a commercial agreement with the Executive Clinic at Mayo Clinic Arizona, marking a significant milestone toward establishing OpenDNA as a standard in preventive genomics. Implementation within the Mayo Clinic executive program is underway.
- Digital Presence: Our new website (https://www.open-dna.com) launched this year, providing updated clinical resources and facilitating new referrals.
- Sales & Distribution: Annual sales reached $151,000, with over 700 tests delivered. OpenDNA tests are now utilized in more than 25 clinics nationwide, supported by our distributor McKesson and an expanding sales force.
Clinical Development
- Published Research: OpenDNA’s approach was validated in a July 2025 publication in Frontiers in Genetics, demonstrating that our polygenic risk scoring (PRS) for coronary artery disease significantly enhances physician decision-making and patient care. CardioRisk+ influenced clinical management in two-thirds of cases, improving patient engagement and preventive interventions Impact of polygenic risk score (PRS) for coronary artery disease on physician decision-making and patient care.
- Study results presented at the ACC: April 2025, the results of OpenDNA’s joint study with Mayo Clinic comparing OpenDNA’s cardiovascular disease prediction to CAC were presented in a poster at the American College of Cardiology. AI-Based Coronary Risk Assessment Integrating Poligenic Risk with Coronary Calcium.
- Machine Learning Advances: A November 2025 study in BMC Medical Genomics highlighted our advanced machine learning techniques for coronary artery disease risk prediction in early middle-aged adults Advanced machine learning techniques for coronary artery disease risk prediction in early middle-aged adults | BMC Medical Genomics.
- Clinical Tools: We introduced a feature enabling physicians to assess baseline risk prior to genetic testing, supporting more effective patient risk communication and test selection. Additionally, our team is developing an AI assistant to help clinicians and patients interpret OpenDNA results and take actionable steps.
Requests & Opportunities
We invite your continued support in the following areas:
- Investor Introductions: Please connect us with angel investors interested in participating in our funding round.
- Clinical Partnerships: Introductions to primary care physicians, concierge practices, preventive cardiologists, and executive or cancer screening programs are highly valued. We are particularly interested in engaging large tertiary centers, such as Mayo Clinic, to further expand our clinical adoption.
Future Plans
Looking ahead to 2026 and beyond, OpenDNA is committed to:
- Expanding Clinical Adoption: We aim to increase the number of clinics utilizing OpenDNA tests, with a focus on engaging additional large tertiary centers and broadening our reach within executive health and cancer screening programs.
- Enhancing AI Capabilities: Our team will continue developing advanced AI tools, including the upcoming assistant for physicians and patients, to further improve risk interpretation and actionable care pathways.
- Product Innovation: We plan to expand our disease panels and introduce new features that empower clinicians to deliver personalized preventive care.
- Research Leadership: OpenDNA will pursue further clinical studies and publications to validate our technology and demonstrate its impact on patient outcomes.
- Strategic Partnerships: We will seek new collaborations with healthcare providers, research institutions, and industry leaders to accelerate the adoption of precision preventive medicine.
- Sustainable Growth: Through targeted fundraising and grant applications, we will ensure financial stability and support ongoing innovation.
Thank you for your ongoing trust and partnership as we shape the future of precision preventive medicine.
Nir Gamliel, CBO
For more information and to contact OpenDNA, click here>>>.
January 2026